Skip to main content

Table 1 Patient characteristics

From: Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases

Parameter All 61 patients 23 patients with bone metastases at first cancer diagnosis 38 patients with metachronous diagnosis of bone metastases
Median age, range (years)* 69, 56-86 67, 57-79 73, 56-86
Median age at first cancer diagnosis, range (years) 68, 53-80 67, 57-79 68, 53-80
Median ECOG PS, range* 1, 0-2 1, 0-2 1, 0-2
Median interval, range (months) 22, 0-159 0 51, 5-159
Median PSA doubling time, range (months)* Not applicable Not applicable 2.5, 1-8
Median PSA, range (μg/L)* 49, 3.9-10,302 173, 12-10,302 23, 3.9-727
Median Hb, range (g/dL)* 13.7, 10.0-16.8 13.9, 10.0-16.8 13.4, 10.2-15.2
Median ALP, range (U/L)* 118, 44-2742 184, 56-2742 102, 44-641
Median LDH, range (U/L)* 206, 158-784 357, 190-784 196, 158-781
Hypo- or hypercalcemia* 0 0 0
Bone pain* 30 11 19
  49% 48% 50%
Gleason score < 7, 7, >7** 6, 11, 27 2, 5, 11 4, 6, 16
  14%, 25%, 61% 11%, 28%, 61% 15%, 23%, 62%
Other distant metastases* 19 8 11
  31% 35% 29%
≤10 bone metastases, >10, 26, 29, 6 6, 12, 5 20, 17, 1
superscan 43%, 48%, 10% 26%, 52%, 22% 53%, 45%, 3%
Initial prostatectomy or radical 10 0 10
radiotherapy 16%   26%
Taxotere treatment 29 12 17
  48% 52% 45%
Zoledronic acid treatment 44 18 26
  72% 78% 68%
Radioisotope treatment 8 5 3
  13% 22% 8%
Alive at the time of analysis 34 14 20
  56% 61% 53%
Median follow-up of living patients, range (months) 25, 6-84 29, 9-84 23, 6-67
  1. * when diagnosed with bone metastases
  2. ** unknown in 5 patients with synchronous and 12 patients with metachronous diagnosis
  3. ECOG PS: Eastern Cooperative Oncology Group performance status, PSA: prostate-specific antigen, Hb: haemoglobin, ALP: alkaline phosphatase, LDH: lactate dehydrogenase